linjc16/ctgov huggingface dataset:
Early Lactate Clearance Rate in Sepsis

Study Overview
=================
Brief Summary
-----------------
To assess the Influence of early lactate clearance rate monitoring in patients with sepsis.

Official Title
-----------------
Monitoring and Guidance of Early Lactate Clearance Rate in Patients With Sepsis

Conditions
-----------------
Early Lactate Clearance

Intervention / Treatment
-----------------
* Diagnostic Test: lactate clearance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients whose blood lactate level reached or exceeded 2.0 mEq / L Exclusion Criteria: Incomplete clinical data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| lactate group<br>Lactate early guide resuscitation | Diagnostic Test: lactate clearance<br>* Lactate clearance rate was monitored within 6 hours after admission<br>|
| control group<br>early guide resuscitation without lactate | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-hospital 60days mortality | In-hospital up to 60 days mortality of sepsis | In-hospital 60 days | 
| ICU mortality | ICU up to 30 days mortality of sepsis | up to 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sepsis, lactate, early
Titanium Tacked Soft Tissue Stabilization : A Novel Technique For Free Gingival Graft Fixation

Study Overview
=================
Brief Summary
-----------------
A case series study on ten patients with lack of keratinization in the non-esthetic area .the purpose of the study is the evaluation of using the titanium tacks in free gingival graft fixation as an alternative to the conventional suturing techniques or the tissue adhesives.

Detailed Description
-----------------
A case series study conducted on 10 patients with lack of keratinization in the non- esthetic areas for clinical evaluation of the effeciancy of the titanium tacks in free gingival graft fixation in terms of the amount of the graft shrinkage through out a six months follow up period . the records will be taken through imagej software for comparing the graft surface area at 1 , 3 and six months .

Official Title
-----------------
Titanium Tacked Soft Tissue Stabilization : A Novel Technique For Free Gingival Graft Fixation

Conditions
-----------------
Lack of Keratinized Gingiva

Intervention / Treatment
-----------------
* Device: titanium tacks or pins


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient with lack of keratinization in the non-esthetic areas Exclusion Criteria: patients on chemotherapy patients on radiotherapy smokers patients with bad oral hygiene
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Device Feasibility
Intervention Model: Single Group Assignment
Interventional Model Description: Using the titanium tacks in free gingival graft fixation instead of conventional suturing.
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: titanium tacks or pins|using tacks or pins made of titanium 2.5 mm diameter and 4mm length for free gingival graft fixation.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluation of the amount of the free gingival graft contraction when being fixed using the titanium tacks( bone tacks) | evaluating the amount of graft contraction by a software standardized surface area calibration of digital photographs taken at one, three, and six months postoperatively | 6 months |
Cabergoline Effect on Blood Sugar in Type 2 Diabetics

Study Overview
=================
Brief Summary
-----------------
Diabetic patients with poorly control blood sugar are prescribed cabergoline for 1 months and their blood glucose is evaluated.

Official Title
-----------------
Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics

Conditions
-----------------
Diabetes Type 2

Intervention / Treatment
-----------------
* Drug: Cabergoline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes HbA1C>7 Exclusion Criteria: HbA1C>10 Psychiatric disorders
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Cabergoline|0,5mg per week|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FBS (fasting blood sugar) |  | 30days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1C |  | 30days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes mellitus, FBS, HbA1C, Cabergoline
Eye Detection to Identify Novel Coronavirus Infection

Study Overview
=================
Brief Summary
-----------------
The eye characteristics of patients with COVID-19 and those without the disease were analyzed, and whether they had the disease or not was judged according to the eye characteristics.

Detailed Description
-----------------
To test the accuracy of a non-invasive eye monitoring that can be widely used for screening in judging patients with novel coronavirus infection.

Official Title
-----------------
Risk Screening Based on Feature Recognition and Detection of Eye Surface Images of COVID-2019 Patients and Statistical Analysis of High-dimensional Data

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Diagnostic Test: Novel coronavirus infection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All participants were provided with written informed consent at the time of recruitment； Age ≥ 18 and ≤ 75 (informed consent signed by guardian under 18) Meet the diagnostic criteria of novel coronavirus (2019-COVID-19) infection Exclusion Criteria: Does not meet any of the inclusion criteria

Ages Eligible for Study
-----------------
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Novel coronavirus infection<br>All patients were diagnosed according to the diagnostic criteria of the National Health Commission of China and confirmed by RT-PCR detection of viral nucleic acids. | Diagnostic Test: Novel coronavirus infection<br>* Using eye examination to judge whether novel coronavirus is infected or not.<br>|
| Not infected by novel coronavirus<br>Healthy controls and patients with liver disease | |
| Recovered patients with nucleic acid negative after infection with novel coronavirus<br>Novel coronavirus nucleic acid changed from positive to negative. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection and analysis of eye characteristics of patients encoding criteria, annotation of ocular feature | Ocular pathological features | 1DAY |
Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if a new treatment is effective for the treatment of recurrent symptomatic oral herpes virus infections.

Official Title
-----------------
A Randomized, Double-blind, Parallel, Placebo-controlled Study for the Assessment of the Safety and Efficacy of BTL-TML-HSV for the Treatment of Recurrent Symptomatic Oral Herpes Virus Infection

Conditions
-----------------
Oral Herpes Simplex

Intervention / Treatment
-----------------
* Drug: BTL TML HSV
* Drug: Matching placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical history of recurrent cold sores averaging 2 or more episodes per year Experiences prodromal symptoms (tingling, burning, itching) of cold sores Herpes Simplex Virus seropositive (by blood test) Exclusion Criteria: Immuno-suppressed or taking immunosuppressant medication Use of antiviral therapy directly prior and during the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BTL TML HSV<br> | Drug: BTL TML HSV<br>* Sublingual micro-dosing for 7 days<br>|
| Placebo Comparator: Matching Placebo<br> | Drug: Matching placebo<br>* sublingual dosing for 7 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of Subjects Who Experience a New Cold Sore Outbreak That Proceeds to the Lesion Stage. Of Those Subjects That Take Study Medication (Experience a New Emerging Cold Sore) Those That Proceed to Lesion Stage (Cold Sore Stage - 3 Vesicle or Above). | Subjects start a daily diary based on start of symptoms of a new emerging cold sore and start taking study medication. Subjects note the start time of study medication along with cold sore stage(s)for at least 7 days and up to 14 days. Subjects take study medication for 7 days. Cold Sore stages are 0=Dormant, 1=Prodrome, 2=Inflammation, 3=Vesicle, 4=Ulcer, 5=Crust, 6=Healed. If subjects do not experience a new cold sore outbreak within 7 days, they do not take study medication and are completed with the study. | 7-14 days (depending on time of lesion outbreak - subjects had 7 days to experience a new emerging cold sore) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Herpes Labialis, Herpes Simplex, Herpes
Watchful Waiting of Incisional Hernias

Study Overview
=================
Brief Summary
-----------------
This study is being conducted to gain a better understanding of the quality of life for patients with a diagnosis of primary and recurrent incisional hernias and 1) who decline to have surgery to repair the hernia or 2) patients who cannot have surgery because their health will not allow them or 3O if surgery to repair the hernia is completed. A comparison will be made between those who receive surgery and those who do not.

Detailed Description
-----------------
This study is being conducted to gain a better understanding of the quality of life for patients with a diagnosis of primary and recurrent incisional hernias and 1) who decline to have surgery to repair the hernia or 2) patients who cannot have surgery because their health will not allow them or 3O if surgery to repair the hernia is completed. A comparison will be made between those who receive surgery and those who do not. Subjects will fill out three survey forms on quality of life and pain at baseline and again at six and 12 months. Measurements of change in hernia size will be made, life-style changes such as smoking cessation, weight-loss, tighter control of diabetes will be initiated for outcome comparison with controls.

Official Title
-----------------
Watchful Waiting of Incisional Hernias: A Prospective Trial

Conditions
-----------------
Incisional Hernia, Ventral Hernia, Umbilical Hernia

Intervention / Treatment
-----------------
* Behavioral: smoking cessation
* Behavioral: tighter diabetic control
* Behavioral: diet and exercise program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: abdominal hernia greater than 3 cm2 18 years of age able to give informed consent Exclusion Criteria: abdominal hernia less than 3 cm2 or greater than 127 cm2 unable to return to clinic for follow-up visits

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: smoking cessation|nan|
|Behavioral: tighter diabetic control|nan|
|Behavioral: diet and exercise program|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Develop guidelines for hernia repair |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To measure if life-style changes lower need for hernia repair |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hernia, incisional hernia, ventral hernia, umbilical hernia
Relation Between Serum IGF-1 & BMI In Acne Vulgaris

Study Overview
=================
Brief Summary
-----------------
cross-sectional study in which participants will be recruited at dermatology & Andrology out-patient clinics in Assuit university hospital, Egypt after patients examination by dermatologists & obtaining an informed consent

Official Title
-----------------
Relation Between Serum Insulin Like Growth Factor 1 and Body Mass Index in Acne Vulgaris

Conditions
-----------------
Evaluation of Serum Level of Insulin Like Growth Factor 1

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged from 15 to 45 years old suffering from acne vulgaris. Both sexes. Exclusion Criteria: Insulin resistance and diabetic patients Females with polycystic ovarian syndrome Treatment with drugs that can influence IGF-1level such as corticosteroid, insulin, hypoglycemic agents, and isotretinoin within one year before the date of study. Other causes of acne or acneform eruption as steroid-induced

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of serum level of insulin like growth factor 1 in acne vulgaris | using the Chemiluminescent Microparticle Immunoassay | 1 year |
Analysis of Clinical Characteristics of Hemodialysis Patients With Omicron Infection

Study Overview
=================
Brief Summary
-----------------
By collecting the clinical data of hemodialysis patients with Omicron infection in RenJi Hospital from April 7, 2022 to June 10, 2022, the clinical characteristics of this population were analyzed. And to analyze the risk factors of different clinical outcomes according to the clinical outcome of this population.

Detailed Description
-----------------
This study was a single-center, retrospective, observational study. The research subjects were hemodialysis patients admitted to the Hemodialysis Center of Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine because of omicron infection during the Omicron epidemic period from April 7, 2022 to June 10, 2022. 65 cases were included in the study after excluding those patients who underwent hemodialysis due to acute kidney injury. And they were compared with 195 non-dialysis patients admitted to the hospital in the same period,who were randomly selected, according to the ratio of 1:3.

Official Title
-----------------
Analysis of Clinical Characteristics of Hemodialysis Patients With Omicron Infection

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hemodialysis patients due to chronic kidney disease stage 5 with omicron infection Exclusion Criteria: Patients on hemodialysis due to acute kidney injury

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| hemodialysis patients with omicron infection<br>hemodialysis patients with omicron infection | Other: no intervention<br>* no intervention<br>|
| non-hemodialysis patients with omicron infection<br>non-hemodialysis patients with omicron infection | Other: no intervention<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Viral elimination | both negative for ORF1ab and N genes (Ct value ≥35 by real-time PCR) in two consecutive days. | 2022-4-7 to 2022-6-10 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiovascular events | including acute left heart failure, new symptomatic arrhythmias requiring drug control, acute coronary syndrome | 2022-4-7 to 2022-6-10 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hemodialysis
Levofloxacin Ocular Implant for Ocular Surgery

Study Overview
=================
Brief Summary
-----------------
This is a multi center, open label, interventional study in one eye of 5 subjects scheduled for uncomplicated cataract surgery with administration of a single Levofloxacin Ocular Implant in the posterior sulcus of the surgical eye at the end of cataract surgery.

Official Title
-----------------
An Interventional, Open Label, Non-randomized, Phase Ia Safety and Tolerability Study of Levofloxacin Ocular Implant in Subjects Undergoing Routine Cataract Surgery.

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Drug: Levofloxacin Ocular Implant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of cataract in the intent to treat eye Endothelial cell density in the study eye of at least 2000 cells per mm2 Exclusion Criteria: history of ocular inflammation including, macular degeneration, uveitis, macular edema or corneal edema recent surgery in the study eye subjects receiving a glaucoma device in conjunction with cataract surgery subjects with a compromised posterior capsule during surgery corneal disease that prevents effective imaging of endothelium including Fuch's Dystrophy. sensitivity to fluoroquinolones

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Levofloxacin Ocular Implant<br>Biphasic levofloxacin antibiotic implant | Drug: Levofloxacin Ocular Implant<br>* Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ocular Inflammation | Change assessed according to Standardization of Uveitis Nomenclature (SUN) Grading Scale | 90 days | 
| Endothelial Cell Density | Change in number of central corneal endothelial cells per mm2 | 90 days | 
| Intraocular Pressure (IOP) | Change in IOP measured by Goldmann applenation tonometry | 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Administration procedure | Number of actuation's required to expel implant | 1 week |
Kinetics of Inflammation Markers in Maternal Plasma: Study of the Correlation With the Diagnosis of Chorioamnionitis in Women Hospitalized for Spontaneous Rupture of the Fetal Membranes

Study Overview
=================
Brief Summary
-----------------
The principal aim of this study is to help obstetricians to diagnose chorioamniotic infection early, in cases of premature rupture of the fetal membranes before 34 WA, by proposing earlier and more specific markers of infection than FBC and CRP. The aim is to reduce vital and functional risk of acute chorioamnionitis for the mother, the fetus or the newborn,. If the kinetics profile of one or several markers correlates strongly with the diagnosis of chorioamnionitis, it could be used in clinical practice, possibly in the context of another clinical study. The results of the study presented here are destined to be published in obstetrics journals.

Official Title
-----------------
Kinetics of Inflammation Markers in Maternal Plasma (Interleukins, Matrix Metalloproteinases -MMP): Study of the Correlation With the Diagnosis of Chorioamnionitis in Women Hospitalized for Spontaneous Rupture of the Fetal Membranes (SPROM) Before 34 Weeks of Amenorrhea (WA) With no Modification in the Usual Therapy.

Conditions
-----------------
Patients With Spontaneous Rupture of the Fetal Membranes

Intervention / Treatment
-----------------
* Other: Blood samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Term between 24 and 34 WA Spontaneous rupture of the fetal membranes Singleton pregnancy Age > 18 years Exclusion Criteria: Delivery within the hour following admission Hospitalisation before 24 WA or after 34 WA Hemorrhagic placenta previa or retroplacental hematoma, known auto-immune or inflammatory disease Infection with human immunodeficiency virus (HIV) Refusal to provide consent. Patients provided for in articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the Public Health Code (e.g.: minors, adults under guardianship, etc…)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patients with spontaneous rupture of the fetal membranes<br> | Other: Blood samples<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| determination of plasma cytokines |  | baseline |